Brian Callaghan

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. doi request reprint The association of exposure to lead, mercury, and selenium and the development of amyotrophic lateral sclerosis and the epigenetic implications
    Brian Callaghan
    University of Michigan, Ann Arbor, MI 48109, USA
    Neurodegener Dis 8:1-8. 2011
  2. doi request reprint Headache neuroimaging: Routine testing when guidelines recommend against them
    Brian C Callaghan
    University of Michigan, Ann Arbor, USA
    Cephalalgia 35:1144-52. 2015
  3. pmc Longitudinal patient-oriented outcomes in neuropathy: Importance of early detection and falls
    Brian Callaghan
    From the University of Michigan B C, K K, K M L, M B, A R, R M, J B, E F and the VA Center for Clinical Management Research K M L, J B, Ann Arbor, MI
    Neurology 85:71-9. 2015
  4. pmc Genotype-phenotype correlations in recessive RYR1-related myopathies
    Kimberly Amburgey
    Department of Pediatrics, Taubman Medical Research Institute, University of Michigan Medical Center, 5019 A, Alfred Taubman Biomedical Science Research Building, 109 Zina Pitcher Place, Ann Arbor, MI 48109 2200, USA
    Orphanet J Rare Dis 8:117. 2013
  5. doi request reprint Capturing cases of distal symmetric polyneuropathy in a community
    Brian Callaghan
    Department of Neurology, University of Michigan, 109 Zina Pitcher Place, 4021 BSRB, Ann Arbor, Michigan 48104, USA
    Muscle Nerve 46:943-7. 2012
  6. pmc Diabetic neuropathy: clinical manifestations and current treatments
    Brian C Callaghan
    University of Michigan, Ann Arbor, MI, USA
    Lancet Neurol 11:521-34. 2012
  7. pmc Enhanced glucose control for preventing and treating diabetic neuropathy
    Brian C Callaghan
    Department of Neurology, University ofMichigan, Ann Arbor, Michigan, USA
    Cochrane Database Syst Rev 6:CD007543. 2012
  8. pmc The evaluation of distal symmetric polyneuropathy: a physician survey of clinical practice
    Brian C Callaghan
    Department of Neurology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI 48104, USA
    Arch Neurol 69:339-45. 2012
  9. pmc Tests and expenditures in the initial evaluation of peripheral neuropathy
    Brian Callaghan
    Department of Neurology, University of Michigan, Ann Arbor, MI 48104, USA
    Arch Intern Med 172:127-32. 2012
  10. pmc Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study
    Brian C Callaghan
    University of Michigan, Ann Arbor, Michigan, USA
    Diabetes Care 34:635-40. 2011

Collaborators

Detail Information

Publications15

  1. doi request reprint The association of exposure to lead, mercury, and selenium and the development of amyotrophic lateral sclerosis and the epigenetic implications
    Brian Callaghan
    University of Michigan, Ann Arbor, MI 48109, USA
    Neurodegener Dis 8:1-8. 2011
    ..Perhaps an interaction between the metal exposure and an individual's genetic makeup is required to produce epigenetic changes that ultimately lead to ALS...
  2. doi request reprint Headache neuroimaging: Routine testing when guidelines recommend against them
    Brian C Callaghan
    University of Michigan, Ann Arbor, USA
    Cephalalgia 35:1144-52. 2015
    ..The aim of this article is to determine the patient-level factors associated with headache neuroimaging in outpatient practice...
  3. pmc Longitudinal patient-oriented outcomes in neuropathy: Importance of early detection and falls
    Brian Callaghan
    From the University of Michigan B C, K K, K M L, M B, A R, R M, J B, E F and the VA Center for Clinical Management Research K M L, J B, Ann Arbor, MI
    Neurology 85:71-9. 2015
    ..To evaluate longitudinal patient-oriented outcomes in peripheral neuropathy over a 14-year time period including time before and after diagnosis...
  4. pmc Genotype-phenotype correlations in recessive RYR1-related myopathies
    Kimberly Amburgey
    Department of Pediatrics, Taubman Medical Research Institute, University of Michigan Medical Center, 5019 A, Alfred Taubman Biomedical Science Research Building, 109 Zina Pitcher Place, Ann Arbor, MI 48109 2200, USA
    Orphanet J Rare Dis 8:117. 2013
    ..To date, no clear patterns have been identified in these recessive mutations, though no systematic examination has yet been performed...
  5. doi request reprint Capturing cases of distal symmetric polyneuropathy in a community
    Brian Callaghan
    Department of Neurology, University of Michigan, 109 Zina Pitcher Place, 4021 BSRB, Ann Arbor, Michigan 48104, USA
    Muscle Nerve 46:943-7. 2012
    ..Little is known about what constitutes appropriate diagnostic testing in patients with distal symmetric polyneuropathy (DSP)...
  6. pmc Diabetic neuropathy: clinical manifestations and current treatments
    Brian C Callaghan
    University of Michigan, Ann Arbor, MI, USA
    Lancet Neurol 11:521-34. 2012
    ..Studies are needed to further explore this association, which has implications for the development of new treatments for this common disorder...
  7. pmc Enhanced glucose control for preventing and treating diabetic neuropathy
    Brian C Callaghan
    Department of Neurology, University ofMichigan, Ann Arbor, Michigan, USA
    Cochrane Database Syst Rev 6:CD007543. 2012
    ..Enhanced glucose control is the best studied intervention for the prevention of this disabling condition but there have been no systematic reviews of the evidence...
  8. pmc The evaluation of distal symmetric polyneuropathy: a physician survey of clinical practice
    Brian C Callaghan
    Department of Neurology, University of Michigan, 109 Zina Pitcher Place, Ann Arbor, MI 48104, USA
    Arch Neurol 69:339-45. 2012
    ..To define current clinical practice for evaluating distal symmetric polyneuropathy...
  9. pmc Tests and expenditures in the initial evaluation of peripheral neuropathy
    Brian Callaghan
    Department of Neurology, University of Michigan, Ann Arbor, MI 48104, USA
    Arch Intern Med 172:127-32. 2012
    ..Peripheral neuropathy is a common disorder in which an extensive evaluation is often unrevealing...
  10. pmc Triglycerides and amputation risk in patients with diabetes: ten-year follow-up in the DISTANCE study
    Brian C Callaghan
    University of Michigan, Ann Arbor, Michigan, USA
    Diabetes Care 34:635-40. 2011
    ..To determine the association between triglyceride levels and lower-extremity amputation (LEA) risk in a large diabetic cohort...
  11. pmc Remission and relapse in a drug-resistant epilepsy population followed prospectively
    Brian Callaghan
    University of Michigan, Ann Arbor, Michigan, USA
    Epilepsia 52:619-26. 2011
    ..In addition, we determined clinical predictors of remission and relapse in this population...
  12. doi request reprint Increased mortality persists in an adult drug-resistant epilepsy prevalence cohort
    Brian Callaghan
    Department of Neurology, University of Michigan, Ann Arbor, Michigan, USA
    J Neurol Neurosurg Psychiatry 85:1084-90. 2014
    ..To investigate the cumulative probability of death and the standardised mortality ratio (SMR) in an adult drug-resistant epilepsy (DRE) population...
  13. doi request reprint Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study
    Mamta Jaiswal
    Department of Neurology, University of Michigan, Ann Arbor, MI
    J Diabetes Complications 29:1287-94. 2015
    ..We therefore performed a proof-of-concept pilot study to evaluate the effect of exenatide, a GLP-1 agonist, on measures of DPN and cardiovascular autonomic neuropathy (CAN) in patients with type 2 diabetes (T2D)...
  14. pmc The metabolic syndrome and neuropathy: therapeutic challenges and opportunities
    Brian Callaghan
    Department of Neurology, University of Michigan, Ann Arbor, MI
    Ann Neurol 74:397-403. 2013
    ..Just as importantly, we must continue to investigate the pathophysiology of metabolically induced nerve injury...